In yesterday’s Wall Street session, Centessa Pharmaceuticals plc (NASDAQ:CNTA) shares traded at $3.87, unchanged from the previous session.
As of this writing, 4 analysts cover Centessa Pharmaceuticals plc (NASDAQ:CNTA). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $11.00 and a low of $4.00, we find $4.00. Given the previous closing price of $3.87, this indicates a potential upside of 3.36 percent. CNTA stock price is now 8.09% away from the 50-day moving average and -18.06% away from the 200-day moving average. The market capitalization of the company currently stands at $369.82M.
There are 2 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $5.75 as their price target over the next twelve months.
With the price target reduced from $10 to $5, Morgan Stanley Downgraded its rating from Overweight to Underweight for Centessa Pharmaceuticals plc (NASDAQ: CNTA). On June 17, 2022, BMO Capital Markets recently initiated its ‘Outperform’ rating on the stock quoting a target price of $19, while ‘Jefferies’ rates the stock as ‘Hold’.
In other news, YVER ANTOINE, EVP & Chairman of Development sold 6,970 shares of the company’s stock on Jan 04. The stock was sold for $22,136 at an average price of $3.18. Upon completion of the transaction, the EVP & Chairman of Development now directly owns 751,913 shares in the company, valued at $2.91 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 01, EVP & Chairman of Development YVER ANTOINE sold 9,400 shares of the business’s stock. A total of $36,744 was realized by selling the stock at an average price of $3.91. This leaves the insider owning 761,151 shares of the company worth $2.95 million. A total of 3.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CNTA stock. A new stake in Centessa Pharmaceuticals plc shares was purchased by AFFINITY ASSET ADVISORS, LLC during the first quarter worth $939,000. GEODE CAPITAL MANAGEMENT, LLC invested $52,000 in shares of CNTA during the first quarter. In the first quarter, COMPAGNIE LOMBARD ODIER SCMA acquired a new stake in Centessa Pharmaceuticals plc valued at approximately $23,000. UBS GROUP AG acquired a new stake in CNTA for approximately $6,000. CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. purchased a new stake in CNTA valued at around $2,000 in the second quarter. In total, there are 56 active investors with 76.30% ownership of the company’s stock.
Tuesday morning saw Centessa Pharmaceuticals plc (NASDAQ: CNTA) opened at $3.8300. During the past 12 months, Centessa Pharmaceuticals plc has had a low of $2.88 and a high of $11.19. As of last week, the company has a debt-to-equity ratio of 0.18, a current ratio of 12.50, and a quick ratio of 12.50. The fifty day moving average price for CNTA is $3.5802 and a two-hundred day moving average price translates $4.7231 for the stock.
The latest earnings results from Centessa Pharmaceuticals plc (NASDAQ: CNTA) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.69, missing analysts’ expectations of -$0.57 by -0.12. This compares to -$0.45 EPS in the same period last year. The company reported revenue of $49.03 million for the quarter, compared to $38.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 27.96 percent.
Centessa Pharmaceuticals plc(CNTA) Company Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.